The Ensign Group, Inc. ENSG R2K

Q: What is the current share price of The Ensign Group, Inc. (ENSG)?

As of 2026-07-14 21:23 PDT, The Ensign Group, Inc. (ENSG) trades at $166.73 on NasdaqGS. Its 52-week range is $136.16 to $215.67.

Q: What is the market capitalisation of ENSG?

The Ensign Group, Inc. (ENSG) has a market capitalisation of $9.74B on NasdaqGS.

Q: What is the P/E ratio of ENSG?

ENSG trades at a trailing price-to-earnings (P/E) ratio of 27.15. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.66.

Q: Does ENSG pay a dividend?

The Ensign Group, Inc. (ENSG) currently offers a dividend yield of 0.17%.

Q: What is the return on equity (ROE) of ENSG?

ENSG has a return on equity (ROE) of 16.92%. Its return on capital employed (ROCE) is 9.31%.

Q: Is ENSG a good stock to buy?

This page provides a data-driven analysis of The Ensign Group, Inc. (ENSG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Care Facilities · United States

https://ensigngroup.net

Company Profile ↓

$166.73

+14.56% 1Y

Mkt Cap$9.74B

P/E27.15

P/B3.66

Div. Yield0.17%

52W High$215.67

52W Low$136.16

Book Value$40.84

EPS (TTM)$6.14

Company Overview

The Ensign Group, Inc. provides skilled nursing, senior living, and rehabilitative services. It operates through two segments: Skilled Services and Standard Bearer. The Skilled Services segment provides short and long-term nursing care services for patients with chronic conditions, prolonged illness, and the elderly; specialty care, such as on-site dialysis, ventilator care, cardiac, and pulmonary management; and standard services, such as room and board, special nutritional programs, social services, recreational activities, entertainment, and other services. The Standard Bearer segment leases post-acute care properties to healthcare operators. In addition, the company operates senior living units; and provides ancillary services consisting of digital x-ray, ultrasound, electrocardiograms, sub-acute services, dialysis, respiratory, and long-term care pharmacy and patient transportation to people in their homes or at long-term care facilities, as well as mobile diagnostics. The company operates healthcare facilities in Alabama, Alaska, Arizona, Colorado, Idaho, Iowa, Kansas, Oregon, Nebraska, Nevada, South Carolina, Tennessee, Texas, Utah, Washington, and Wisconsin. The company was incorporated in 1999 and is based in San Juan Capistrano, California.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 16.9%, reflecting efficient use of shareholder capital.

Consistent Profit Growth

Net profit has compounded at 15.9% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 13.2% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $5.03B (+18.8% YoY); net profit $343.97M.
Trailing 12 Months Year-on-year growth — revenue +18.4%, earnings +21.9%.
5-Year Trend Long-term compounding — revenue CAGR 13.2%, profit CAGR 15.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	13.15%
1 Year:	18.40%

Compounded Profit Growth

5 Years:	15.89%
1 Year:	21.90%

Stock Price Performance

1 Year:	+14.56%
6 Months:	-4.04%
3 Months:	-16.73%
1 Month:	+13.37%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 38% of range

$136.16 $215.67

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)51.96 · Neutral

Price Performance

1M+13.37%

3M-16.73%

6M-4.04%

1Y+14.56%

Valuation vs Sector

P/E of 27.15 is above the sector median of 25.41 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 13.2% over 5 years.
Profit CAGR of 15.9% over 5 years.
Generates positive free cash flow.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

27.15

Industry PE

25.41

Forward P/E

20.02

PEG Ratio

1.32

Book Value

$40.84

Price to Book

3.66

P/S

1.66

EV/EBITDA

18.52

Dividend Yield

0.17%

Growth (CAGR)

Revenue 5Y

13.15%

Profit 5Y

15.89%

Revenue (YoY)

18.40%

Earnings (YoY)

21.90%

Profitability & Returns

ROCE

9.31%

ROE

16.92%

ROA

5.41%

Profit Margin

6.89%

Op Margin

8.99%

Gross Margin

16.43%

EPS (Latest Qtr)

$1.67

EPS (TTM)

$6.14

Balance Sheet & Liquidity

Debt/Equity

0.95

Quick Ratio

1.48

Current Ratio

1.56

Debt

$2.24B

Total Assets

$5.61B

Current Assets

Working Capital

Ownership

Promoter Holding

3.52%

Chg in Prom Hold

FII / Inst Holding

94.78%

Chg in FII Hold

-0.13%

Financial Snapshot

Enterprise Value

$9.74B

Total Revenue (TTM)

$5.27B

EBITDA

$556.63M

Free Cash Flow

$291.29M

Operating Cash Flow

$592.20M

Shares Outstanding

58.45M

Gross Margin

16.43%

Payout Ratio

4.15%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ENSG The Ensign Group, Inc. R2K	166.73	27.15	$9.74B	0.17%	9.31%	16.92%	13.15%	15.89%
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2013	Jun 2013	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	471.59M	492.13M	496.39M	514.36M	471.31M	492.92M	512.11M	589.61M	584.70M	599.25M	627.25M	638.54M	668.53M	713.45M	732.49M	770.00M	886.84M	921.35M	940.79M	1.01B	1.03B	1.08B	1.17B	1.22B	1.29B	1.38B
Operating Income	-10.75M	23.29M	20.29M	24.35M	13.64M	15.29M	25.17M	21.98M	21.59M	16.32M	19.81M	20.04M	7.55M	22.03M	25.56M	32.98M	31.77M	29.29M	29.95M	28.74M	30.80M	56.79M	55.43M	55.07M	63.68M	64.85M	66.32M	69.11M	78.23M	74.29M	74.88M	77.87M	79.79M	82.22M	85.97M	89.34M	101.37M	103.90M	96.22M	124.85M
Net Income	-12.15M	12.37M	10.46M	13.53M	2.01M	8.91M	15.17M	13.19M	13.47M	9.17M	11.33M	11.15M	2.84M	12.22M	14.21M	23.13M	22.01M	20.86M	27.37M	28.61M	27.16M	40.85M	40.25M	43.06M	49.21M	49.42M	47.28M	50.34M	57.69M	56.18M	59.85M	63.99M	63.86M	68.83M	71.01M	78.44M	80.28M	84.40M	83.84M	99.67M
Diluted EPS	-0.56	0.55	0.47	0.60	0.09	0.38	0.31	0.25	0.25	0.18	0.22	0.21	0.05	0.23	0.27	0.43	0.41	0.38	0.49	0.51	0.48	0.73	0.73	0.77	0.86	0.87	0.83	0.89	1.01	0.99	1.05	1.12	1.11	1.19	1.22	1.34	1.37	1.44	1.42	1.67

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	1.65B	1.60B	1.75B	2.04B	2.39B	2.63B	3.03B	3.71B	4.24B	5.03B
Operating Income	58.94M	75.65M	90.70M	78.27M	57.94M	72.92M	93.08M	91.85M	43.19M	84.91M	129.18M	223.16M	260.46M	296.82M	255.37M	358.30M	425.31M
Net Income	32.49M	40.53M	47.67M	40.59M	24.04M	35.95M	55.43M	49.99M	40.48M	92.36M	110.53M	170.48M	194.65M	224.68M	209.40M	297.97M	343.97M
Diluted EPS	1.55	1.92	2.21	1.85	0.54	0.78	1.06	0.96	0.77	1.70	1.97	3.06	3.42	3.95	3.65	5.12	5.84

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Sep 2012	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Jun 2016	Dec 2016	Dec 2017	Dec 2018	Jan 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	479.89M	596.34M	-	690.86M	760.32M	493.92M	747.76M	-	1.00B	1.10B	1.18B	2.20B	2.36B	2.55B	2.85B	3.45B	4.18B	4.67B	5.46B
Total Equity	156.02M	187.56M	228.20M	277.49M	-	326.47M	356.10M	258.85M	427.32M	-	456.45M	492.40M	590.93M	611.37M	654.20M	818.08M	1.02B	1.25B	1.49B	1.84B	2.23B
Cash & Equivalents	41.33M	38.85M	72.09M	29.58M	40.69M	40.69M	65.75M	50.41M	41.57M	41.57M	57.71M	42.34M	31.04M	-	59.17M	236.56M	262.20M	316.27M	509.63M	464.60M	503.88M
Long Term Debt	-	-	139.45M	181.56M	-	200.50M	251.90M	68.28M	99.05M	-	275.49M	302.99M	233.13M	-	330.35M	117.65M	152.88M	149.27M	145.50M	141.59M	137.53M
Total Liabilities	-	-	-	-	-	362.98M	403.06M	236.11M	320.77M	-	540.53M	602.37M	579.62M	1.59B	1.71B	1.73B	1.83B	2.20B	2.68B	2.83B	3.23B
Current Liabilities	-	-	83.37M	100.39M	-	121.35M	112.46M	130.43M	179.87M	-	211.93M	225.82M	269.23M	-	343.17M	562.40M	523.07M	582.07M	734.75M	743.43M	894.35M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	46.27M	60.50M	72.69M	82.05M	37.42M	84.88M	33.37M	73.89M	79.54M	210.30M	192.22M	373.35M	275.68M	272.51M	376.67M	347.19M	564.27M
Investing Cash Flow	-80.47M	-57.19M	-156.05M	-84.50M	-65.23M	-172.85M	-168.54M	-210.64M	-113.18M	-151.21M	-247.01M	-58.67M	-173.91M	-186.18M	-182.70M	-390.05M	-513.18M
Financing Cash Flow	31.73M	29.92M	40.86M	13.55M	52.88M	72.62M	126.33M	152.88M	18.27M	-70.34M	82.88M	-137.30M	-76.14M	-32.26M	-612.00K	-2.16M	-11.81M
Capital Expenditure	-21.88M	-28.72M	-40.77M	-38.85M	-29.76M	-53.69M	-60.02M	-65.70M	-54.08M	-50.89M	-71.54M	-	-	-	-	-	-
Free Cash Flow	24.39M	31.78M	31.91M	43.20M	7.67M	31.19M	-26.65M	8.19M	25.46M	159.41M	120.68M	-	-	-	-	-	-
Share Buybacks	-	0	0	174.00K	0	0	0	30.00M	7.29M	0	6.41M	25.00M	10.12M	29.88M	0	0	20.00M
Dividends Paid	3.71M	4.15M	4.64M	6.60M	4.32M	6.30M	7.49M	8.17M	8.72M	9.42M	10.19M	10.83M	11.55M	12.17M	12.89M	13.67M	14.41M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	5.6%	2.7%	4.8%	6.3%	9.3%	9.9%	9.8%	6.9%	8.5%	8.5%
Net Margin %	-	-	-	-	-	-	-	3.0%	2.5%	5.3%	5.4%	7.1%	7.4%	7.4%	5.6%	7.0%	6.8%
ROE %	17.3%	17.8%	17.2%	12.4%	6.8%	13.9%	13.0%	11.0%	8.2%	15.6%	16.9%	20.8%	19.1%	18.0%	14.0%	16.2%	15.4%
ROCE %	-	19.1%	18.3%	13.7%	8.9%	20.1%	16.4%	11.6%	4.9%	9.3%	6.4%	11.3%	11.2%	10.3%	7.4%	9.1%	9.3%

Shareholding Pattern

Insiders

3.52%

Institutions

94.78%

Public Float

98.24%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	12.60%	7.36M	$1.24B
2	BAILLIE GIFFORD & CO	8.26%	4.83M	$810.65M
3	Vanguard Portfolio Management LLC	5.34%	3.12M	$524.12M
4	Vanguard Capital Management LLC	4.44%	2.59M	$435.53M
5	FMR, LLC	3.93%	2.30M	$385.74M
6	State Street Corporation	3.53%	2.06M	$346.50M
7	Wasatch Advisors LP	3.52%	2.06M	$345.68M
8	Geode Capital Management, LLC	2.89%	1.69M	$283.41M
9	Capital Research Global Investors	2.40%	1.40M	$235.51M
10	Price (T.Rowe) Associates Inc	2.24%	1.31M	$219.74M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ENSG

Google News Mon, 13 Jul 2026

The Ensign Group (ENSG) Slid Amid Regulatory and Short-Seller-Related Concerns - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOZUllTU95NDA3WXFtaDFzRHJoU19fSG1iR1ZJLTFzbnFZMVVNNWE3Ml8wZ2NmMThESEFDaGFMY016Y2QtZ3drbVJYM3kxcFRKYk5aaDFtWGF1UEdMazA5LVF0dWN6dE15bXhCZUFPZzVkN2xJczllUDJqQjdRc0EweVJEcUluMUlpb2wzek…

Google News ue, 14 Jul 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Ensign Group, Inc. - ENSG - FinancialContent

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxNa2l2d1NfRUVaQjZWVExwbWpVSWpaME1KQ2dzSWtPbDNfQUR0bkt2RldQeUVJVXlqeW9ZMzhtV2NPME5WaVZDX0dQSmE5OTV5OHhKMXgyTDhGd09LSVpQUDQzT1hqMVU5dVRndXl0VWdpdnNqRGV3NDhIU3lmNkZrWmJrMnQ0RnB3U1YtMl…

Google News hu, 09 Jul 2026

The Ensign Group (ENSG) Shares Fall Amid Activist Forensic - GlobeNewswire

<a href="https://news.google.com/rss/articles/CBMimgJBVV95cUxNQk5VeXktRTB4NndiSlEwNlJndkM3d1Mwc3h2VDYyRUZZWGViQVZwaWx4ekdjUC1zaG1tby1uMHU2MUVUSXRWaGQ2SVYxdmlXWVZILXh5WnZ6OXAtSnEwblpzaTAxNEJlYTlPdVhlc3hab1BDeVNESGY0cmpuX3JYUVMxOWRqVTltbHV2Zl…

Google News hu, 11 Jun 2026

ENSG Investor Alert: Levi & Korsinsky Investigates The Ensign Group (ENSG) for Potential Securities Fraud - Business Wire

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxNbGFRaWJIVFMzMmFrenBhRFptQXgtMVJUamxUYVhCY0Vrckg5VXgxVmh3dm1DbjlzTGZNbE1NdjNRbGc2TjBGQnZya1lNTDBmMmxXRGtVRjE1czhoOGw1VE1Gcy02ZTRtOXhnNkhXU3Y1U3huaWF1QU1tcl9Ud1ZVTFI2TExtT0FPYkEzRV…

Google News ue, 09 Jun 2026

Is the Sudden Drop in Ensign Stock an Opportunity or a Warning Sign? - Trefis

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxOaWQzeHZOUTZyVjZKSnlPMEp4MVo3VWtRbC1oVVJLb0pnT2NicjMyVXBSSFd6Z1J4cjBib2hPeF9WOG9LNVh4YXpLRnRwemUwREtORmhlb25DS0F4cnhkUXVwWUlJclkzcW1aUDd0UHNjbURHVDllODUxVjctaXdQd0QxN1ltTTRyOVhkMV…

Google News hu, 25 Jun 2026

Ensign Group (ENSG) Stock Weighs Recent Pullback Against DCF Fair Value Estimate - simplywall.st

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQWm9BYmY4emRiRWc0T0hZM1BKcUQyYUZHYjZxOHNZazhWeU1FOEZTVnZfNGdfM3RoMkYwYWtTZjJ5YUFsTUxGdzFfendpRlBHbGlQaktPOTR2bGtST25vcE1TcXkwaWpJemd4anhkUlRhT0c0blR1dHRmY0Z5VEFDSEp2TTZtTUR1Y05Yck…

ENSG — Frequently Asked Questions

What is the current share price of The Ensign Group, Inc. (ENSG)?

As of 2026-07-14 21:23 PDT, The Ensign Group, Inc. (ENSG) trades at $166.73 on NasdaqGS. Its 52-week range is $136.16 to $215.67.

What is the market capitalisation of ENSG?

The Ensign Group, Inc. (ENSG) has a market capitalisation of $9.74B on NasdaqGS.

What is the P/E ratio of ENSG?

ENSG trades at a trailing price-to-earnings (P/E) ratio of 27.15. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.66.

Does ENSG pay a dividend?

The Ensign Group, Inc. (ENSG) currently offers a dividend yield of 0.17%.

What is the return on equity (ROE) of ENSG?

ENSG has a return on equity (ROE) of 16.92%. Its return on capital employed (ROCE) is 9.31%.

Is ENSG a good stock to buy?

This page provides a data-driven analysis of The Ensign Group, Inc. (ENSG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

The Ensign Group, Inc. ENSG R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

The Ensign Group (ENSG) Slid Amid Regulatory and Short-Seller-Related Concerns - Yahoo Finance

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Ensign Group, Inc. - ENSG - FinancialContent

The Ensign Group (ENSG) Shares Fall Amid Activist Forensic - GlobeNewswire

ENSG Investor Alert: Levi & Korsinsky Investigates The Ensign Group (ENSG) for Potential Securities Fraud - Business Wire

Is the Sudden Drop in Ensign Stock an Opportunity or a Warning Sign? - Trefis

Ensign Group (ENSG) Stock Weighs Recent Pullback Against DCF Fair Value Estimate - simplywall.st

ENSG — Frequently Asked Questions

What is the current share price of The Ensign Group, Inc. (ENSG)?

What is the market capitalisation of ENSG?

What is the P/E ratio of ENSG?

Does ENSG pay a dividend?

What is the return on equity (ROE) of ENSG?

Is ENSG a good stock to buy?

Explore More